Hypertension and lipids: Lipid factors in the hypertension syndrome

Current Hypertension Reports

Volumn 4, Issue 6, 2002, Pages 458-463

  Sander, Gary E ^a   Giles, Thomas D ^a  

^a LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LIPID;

BLOOD; BLOOD PRESSURE; HUMAN; HYPERTENSION; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; RISK FACTOR; SYNDROME; UNITED STATES;

BLOOD PRESSURE; HUMANS; HYPERTENSION; LIPIDS; RISK FACTORS; SYNDROME; UNITED STATES;

EID: 0036886553     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-002-0026-1     Document Type: Article

References (32)

1. Wilson PW, Kannel WB, Silbershatz H, D'Agostino RB: Clustering of metabolic factors and coronary heart disease. Arch Intern Med 1999, 159: 1104-1109.
2. Haffner SM, Lehto S, Ronnemaa T, et al.: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998, 339: 229-234.
3. Poulter N: Coronary heart disease is a multifactorial disease. Am J Hypertens 1999, 12: 92S-95S.
4. Fagan TC, Deedwania PC: The cardiovascular dysmetabolic syndrome. Am J Med 1998, 105: 77S-82S.
5. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001, 285: 2486-2497.
6. Ford ES, Giles WH, Dietz WH: Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Survey. JAMA 2002, 287: 356-359.
7. Lloyd-Jones DM, Evans JC, Larson MG, et al.: Cross-classification of JNC VI blood pressure stages and risk groups in the Framing-ham Heart Study. Arch Intern Med 1999, 159: 2206-2212.
8. Martin MJ, Hulley SB, Browner WS, et al.: Serum cholesterol, blood pressure, and mortality: implications from a cohort of 361,662 men. Lancet 1986, 2: 933-936.
9. Stern N, Grosskopf I, Shapira I, et al.: Risk factor clustering in hypertensive patients: impact of the reports of NCEP-II and second joint task force on coronary prevention on JNC-VI guidelines. J Intern Med 2000, 248: 203-210.
10. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA 1993, 269: 3015-3023.
11. Pearson TA, Laurora I, Chu H, Kafonek S: The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-low-ering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000, 160: 459-467.
12. Panza JA, Casino PR, Kilcoyne CM, Quyyumi AA: Role of endothelium-derived nitric oxide in the abnormal endothe-lium-dependent vascular relaxation of patients with essential hypertension. Circulation 1993, 87: 1468-1474.
13. Casino PR, Kilcoyne CM, Quyyumi AA, et al.: The role of nitric oxide in endothelium-dependent vasodilation of hypercho-lesterolemic patients. Circulation 1993, 88: 2541-2547.
14. Pepine CJ: Why vascular biology matters. Am J Cardiol 2001, 88(Suppl): 5K-9K.
15. Cai H, Harrison DG: Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res 2000, 87: 840-844.
16. Dzau VJ: Tissue renin-angiotensin system in myocardial hypertrophy and failure. Arch Intern Med 1993, 153: 937-942.
17. Nickenig G, Strehlow K, Baumer AT, et al.: Negative feedback regulation of reactive oxygen species on AT1 receptor gene expression. Br J Pharmacol 2000, 131: 795-803.
18. Nickenig G, Jung O, Strehlow K, et al.: Hypercholesterolemia is associated with enhanced angiotensin AT1-receptor expression. Am J Physiol 1997, 272(6 Pt 2):H2701-H2707.
19. Strehlow K, Wassmann S, Bohm M, Nickenig G: Angiotensin AT1 receptor over-expression in hypercholesterolaemia. Ann Med 2000, 32: 386-389.
20. Nickenig G, Sachinidis A, Michaelsen F, et al.: Upregulation of vascular angiotensin II receptor gene expression by low-density lipoprotein in vascular smooth muscle cells. Circulation 1997, 95: 473-478.
21. Nickenig G, Sachinidis A, Seewald S, et al.: Influence of oxidized low-density lipoprotein on vascular angiotensin II receptor expression. J Hypertens 1997, 15:S27-S30.
22. Nickenig G, Strehlow K, Roeling J, et al.: Salt induces vascular AT1 receptor overexpression in vitro and in vivo. Hypertension 1998, 31: 1272-1277.
23. Strehlow K, Nickenig G, Roeling J, et al.: AT1 receptor regulation in salt-sensitive hypertension. Am J Physiol 1999, 277(5 Pt 2):H1701-H1707.
24. Panza JA, Quyyumi AA, Callahan TS, Epstein SE: Effect of antihypertensive treatment on endothelium-dependent vascular relaxation in patients with essential hypertension. J Am Coll Cardiol 1993, 21: 1145-1151.
25. Borghi C, Veronesi M, Prandin MG, et al.: Statins and blood pressure regulation. Curr Hypertens Rep 2001, 3: 281-288.
26. Sung BH, Izzo JL Jr, Wilson MF: Effects of cholesterol reduction on BP response to mental stress in patients with high cholesterol. Am J Hypertens 1997, 10: 592-599.
27. Nickenig G, Baumer AT, Temur Y, et al.: Statin-sensitive dysreg-ulated AT1 receptor function and density in hypercholester-olemic men. Circulation 1999, 100: 2131-2134.
28. Wassmann S, Laufs U, Baumer AT, et al.: HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholes-terolemic hypertension via reduced production of reactive oxygen species. Hypertension 2001, 37: 1450-1457.
29. Tonolo G, Melis MG, Formato M, et al.: Additive effects of simvastatin beyond its effects on LDL cholesterol in hypertensive type 2 diabetic patients. Eur J Clin Invest 2000, 30: 980-987.
30. Glorioso N, Troffa C, Filigheddu F, et al.: Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia. Hypertension 1999, 34: 1281-1286.
31. Nazzaro P, Manzari M, Merlo M, et al.: Distinct and combined vascular effects of ACE blockade and HMG-CoA reductase inhibition in hypertensive subjects. Hypertension 1999, 33: 719-725.
32. Nickenig G, Harrison DG: The AT1-type angiotensin receptor in oxidative stress and atherogenesis. Part II: receptor regulation. Circulation 2002, 105: 530-536.